Back to Treatments

Treatment

Ranibizumab

1
Conditions
381
Trials
60K
Participants
45%
Average Safety

Condition Evidence

Macular Degeneration

381 trials · 60K participants

88% effectiveness · 45% safety
Ranibizumab | DFDA